KR20190031182A - Use of a peptide as a therapeutic agent for autoimmune disease or bone disease - Google Patents
Use of a peptide as a therapeutic agent for autoimmune disease or bone disease Download PDFInfo
- Publication number
- KR20190031182A KR20190031182A KR1020180110473A KR20180110473A KR20190031182A KR 20190031182 A KR20190031182 A KR 20190031182A KR 1020180110473 A KR1020180110473 A KR 1020180110473A KR 20180110473 A KR20180110473 A KR 20180110473A KR 20190031182 A KR20190031182 A KR 20190031182A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- peptide
- bone
- disease
- present
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 82
- 208000020084 Bone disease Diseases 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title abstract description 15
- 229940124597 therapeutic agent Drugs 0.000 title abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 title abstract description 8
- 206010003246 arthritis Diseases 0.000 claims abstract description 16
- 150000001413 amino acids Chemical group 0.000 claims description 17
- 210000000988 bone and bone Anatomy 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 11
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 10
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 9
- 239000004473 Threonine Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 7
- 235000009582 asparagine Nutrition 0.000 claims description 7
- 229960001230 asparagine Drugs 0.000 claims description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 208000016738 bone Paget disease Diseases 0.000 claims description 2
- 208000019664 bone resorption disease Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 235000013930 proline Nutrition 0.000 claims 5
- 235000004400 serine Nutrition 0.000 claims 5
- 235000008521 threonine Nutrition 0.000 claims 4
- 235000004554 glutamine Nutrition 0.000 claims 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 32
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 23
- 210000000068 Th17 cell Anatomy 0.000 abstract description 15
- 210000004027 cell Anatomy 0.000 abstract description 10
- 230000004069 differentiation Effects 0.000 abstract description 9
- 238000010171 animal model Methods 0.000 abstract description 4
- 210000002997 osteoclast Anatomy 0.000 description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 9
- 210000000963 osteoblast Anatomy 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 7
- 208000009386 Experimental Arthritis Diseases 0.000 description 6
- 101100243377 Mus musculus Pepd gene Proteins 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- CQTGBCFGAAYOCY-ZCRNMIQFSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(C)=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(C)C)C(N)=O CQTGBCFGAAYOCY-ZCRNMIQFSA-N 0.000 description 5
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 108010088535 Pep-1 peptide Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000002917 arthritic effect Effects 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 102000054350 human CHI3L1 Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VOOGILFUHUXBEV-ZBRNBAAYSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound OC[C@H](N)C(O)=O.OC(=O)[C@@H]1CCCN1 VOOGILFUHUXBEV-ZBRNBAAYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- -1 Pep3 Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000000610 foot bone Anatomy 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010037248 lantibiotic Pep5 Proteins 0.000 description 1
- SRCAXTIBNLIRHU-JJKPAIEPSA-N lantibiotic pep5 Chemical compound N([C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N\C(=C/C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N\C(=C(/C)S)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)C(=O)CC SRCAXTIBNLIRHU-JJKPAIEPSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
본 발명은 골질환 치료제로서의 펩타이드의 용도에 관한 것으로, 보다 구체적으로 본 발명의 일반식 1로 기재되는 아미노산 서열로 구성된 펩타이드, 및 상기 펩타이드의 골다공증 등을 포함하는 골질환 치료 용도에 관한 것이다.The present invention relates to the use of a peptide as a therapeutic agent for bone diseases, more specifically, to a peptide consisting of the amino acid sequence represented by the general formula (1) of the present invention, and to a bone disease treatment including osteoporosis of the peptide.
골 조직은 콜라겐, 당단백과 같은 세포외기질(extracellular substance)과 조골세포(osteoblast), 파골세포(osteoclast), 골세포 등 여러 종류의 세포들로 구성되어 있다. 특히, 조골세포(osteoblast)와 파골세포(osteoclast)의 상호 균형은 건강한 골격계 형성에 필수적이다. 즉, 골대사(bone metabolism)와 골재형성(bone remodeling)은 뼈 기질(bone matrix)를 만드는 조골세포(osteoblasts)와 뼈를 흡수하는 파골세포(osteoclasts) 사이의 균형적인 활동이 뼈의 항상성 유지에 중요하다.Bone tissue is composed of various kinds of cells such as extracellular substance such as collagen and glycoprotein, osteoblast, osteoclast, and osteocyte. In particular, the balance between osteoblasts and osteoclasts is essential for a healthy skeletal system. In other words, bone metabolism and bone remodeling are important for maintaining homeostasis of bone in the balance between osteoblasts that make up the bone matrix and osteoclasts that absorb bone. Do.
골 조직은 콜라겐, 당단백과 같은 세포외기질(extracellular substance)과 조골세포(osteoblast), 파골세포(osteoclast), 골세포 등 여러 종류의 세포들로 구성되어 있다. 또한, 파골세포에 의한 골 흡수와 조골세포에 의한 새로운 골 기질 형성 및 무기질화 과정이 반복적으로 일어나는 대사기관으로, 조골세포의 활동으로 인한 골 형성이 파골세포의 활동으로 인한 골 흡수보다 많게 된다. 골의 재형성은 성장이 끝난 후 오래된 골을 제거하고 다시 새로운 골로 대치하는 과정으로, 부갑상선 호르몬(PTH), 칼시토닌, 에스트로겐 등과 같은 호르몬과 IGFI(insulin-like growth factor I) 등의 골조직에서 분비되는 다양한 성장인자, TNF-α(tumor necrosis factor-α) 등과 같은 사이토카인(cytokines)을 통해 조골세포와 파골세포의 활성 균형을 조절하며 항상성을 유지시킨다. 이러한 조골세포와 파골세포의 균형이 깨지는 경우 골다공증이나 관절염과 같은 질환이 유발하게 된다.Bone tissue is composed of various kinds of cells such as extracellular substance such as collagen and glycoprotein, osteoblast, osteoclast, and osteocyte. In addition, bone resorption by osteoclasts and new bone matrix formation and mineralization by osteoblasts are repeated metabolic processes, and bone formation due to osteoblast activity is greater than bone resorption due to osteoclast activity. The bone resurfacing is the process of removing old bone after growth and replacing it with a new bone. It is secreted from bone tissues such as hormone such as parathyroid hormone (PTH), calcitonin, estrogen, etc. and insulin-like growth factor I It regulates the activity balance of osteoblasts and osteoclasts through cytokines such as various growth factors and tumor necrosis factor-alpha (TNF-α), and maintains homeostasis. If the balance between osteoblasts and osteoclasts is broken, it will lead to diseases such as osteoporosis and arthritis.
특히, 조골세포와 파골세포의 균형이 깨지게 되면 파골세포에 의한 지나친 뼈의 파괴가 일어나게 되고 골다공증과 같은 질환으로 이어지게 되는 것이다. 이러한 파골세포는 골대사 과정에서 뼈의 흡수를 담당하는 특화된 세포로서 전구세포인 단핵구(monocyte)나 대식세포(macrophage)로부터 분화 프로그램을 통해서 형성된다. 또한, 파골세포는 αvβ3 인테그린(integrin) 등을 통해 골에 결합하며 산성 환경을 조성하는 한편 각종 콜라게네이즈(collagenase) 및 프로테아제(protease)를 분비하여 골 흡수(bone resorption)를 일으키므로, 이러한 파골세포를 억제가 골 질환 치료의 효과적인 방법이 될 수 있다.In particular, when the balance between osteoblasts and osteoclasts is broken, excessive bone destruction by osteoclasts occurs, leading to diseases such as osteoporosis. These osteoclasts are specialized cells that are responsible for bone resorption in the bone metabolism process and are formed through differentiation programs from monocytes or macrophages, which are progenitor cells. In addition, since osteoclasts bind to bone through αvβ3 integrin or the like to form an acidic environment and secrete various collagenases and proteases to cause bone resorption, Suppression of cells can be an effective method of treating bone disease.
한편, 최근 CD4+ T 세포 계통인 Th17 세포가 자가 면역질환의 염증 유발과 진행에 핵심적인 역할을 한다는 것이 밝혀지고 있으며, 이러한 Th17 세포의 중요성은 이 세포에서 분비된 IL-17이 자가면역질환과 직접적인 관계가 있는 것으로 밝혀짐으로서 더욱 커지고 있다.In addition, it has been recently shown that Th17 cells, a CD4 + T cell line, plays a key role in inflammation induction and progression of autoimmune diseases. The significance of such Th17 cells is that IL-17 secreted from these cells is directly associated with autoimmune diseases But it is getting bigger as it is revealed that there is a relationship.
또한, Th17 세포는 골파괴의 주요 원인인 RANKL 및 여러 염증성 사이토카인을 유도하고(Chabaud and Miossec, 2001; Connell and McInnes, 2006), 이를 통해 염증 및 관절파괴 기전을 더욱더 활성화 하는 것으로 알려져 있다. 따라서, Th17 세포는 류마티스관절염을 포함하는 자가면역질환, 골질환에 관련된 신호전달 과정에서 핵심 병인 세포로 인정 받고 있으므로, Th17 세포 분화를 효과적으로 억제하는 후보물질의 발굴이 요구되고 있다.In addition, Th17 cells induce RANKL and several inflammatory cytokines (Chabaud and Miossec, 2001; Connell and McInnes, 2006), which are known to further activate the inflammatory and joint destruction mechanisms. Therefore, since Th17 cells are recognized as a key tumor cell in the signal transduction process related to autoimmune diseases including osteoarthritis and bone diseases, candidate substances that effectively inhibit Th17 cell differentiation are required to be discovered.
이에, 본 발명자들은 치료제로서의 부작용을 최소화시키면서 유효한 치료 효과를 갖는 새로운 골질환 치료제를 개발하기 위해 노력한 결과, 본 발명에서 제조한 펩타이드가 골다공증을 포함하는 골질환 치료에 유용하게 사용될 수 있음을 밝힘으로써, 본 발명을 완성하였다.Accordingly, the present inventors have made efforts to develop a new therapeutic agent for bone diseases having an effective therapeutic effect while minimizing side effects as therapeutic agents, and as a result, it has been found that the peptide prepared in the present invention can be effectively used for the treatment of bone diseases including osteoporosis , Thereby completing the present invention.
본 발명의 목적은 골질환(bone disease) 예방 및 치료용 펩타이드를 제공하기 위한 것이다.It is an object of the present invention to provide a peptide for the prevention and treatment of bone disease.
상기 목적을 달성하기 위하여, 본 발명은 In order to achieve the above object,
하기 서열번호 1로 기재되는 일반식 1의 아미노산 서열로 구성된 펩타이드, 및 상기 펩타이드를 유효성분으로 함유하는 골질환 예방 및 치료용 약학적 조성물, 또는 골질환 예방 및 개선용 건강식품을 제공한다.A peptide comprising the amino acid sequence of the
[일반식 1][Formula 1]
(X1-X2-X3)n (X 1 -X 2 -X 3 ) n
상기 식에서, X1 내지 X3은 각각 프롤린(Proline; P), 세린(Serine; S), 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이고, Wherein X 1 to X 3 are each independently selected from the group consisting of proline P, serine S, threonine T, glutamine Q, asparagine N, and cysteine C ), ≪ / RTI >
n은 1 내지 10의 정수이며, 단 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP를 포함하고, 동시에 n=1 내지 3 경우는 제외함. n is an integer of 1 to 10, provided that the amino acid sequence of the general formula (1) includes the PSP represented by SEQ ID NO: 2 and n = 1 to 3 at the same time.
본 발명의 펩타이드들은 자가면역질환에 관련된 T 세포(T cell)의 활성 및 Th17 세포(T helper 17 cell) 분화를 유의적으로 억제시키며, 관절염 동물모델에서 현저한 관절염 치료 및 개선 효과를 갖는 것을 확인하였으므로, 상기 펩타이드들은 골질환 치료제에 유효성분으로 이용될 수 있다.The peptides of the present invention significantly inhibited T cell (T cell) activity and Th17 cell (
도 1은 본 발명의 합성 펩타이드에 의한 활성 T 세포 population(%)을 나타낸 도이다.
도 2는 본 발명의 합성 펩타이드에 의한 활성 T 세포 population(%)을 그래프로 나타낸 도이다.
도 3은 본 발명의 합성 펩타이드에 의한 T 세포 활성화 억제율(%)을 나타낸 도이다.
도 4는 본 발명의 합성 펩타이드에 Th17 세포 분화 억제 효능을 나타낸 도이다.
도 5는 콜라겐 유도 관절염 마우스 모델의 제조과정 및 본 발명에 따른 펩타이드의 투여 시기를 개략적으로 나타낸 모식도이다.
도 6은 본 발명의 Pep1 펩타이드의 관절염 개선 효과를 나타낸 도이다.
도 7은 본 발명의 Pep2 펩타이드의 관절염 개선 효과를 나타낸 도이다.
도 8은 본 발명의 Pep4 펩타이드의 관절염 개선 효과를 나타낸 도이다.
도 9는 본 발명의 Pep6 펩타이드의 관절염 개선 효과를 나타낸 도이다.1 is a graph showing the population (%) of active T cells by the synthetic peptides of the present invention.
Figure 2 is a graph showing the population (%) of active T cells by the synthetic peptide of the present invention.
Fig. 3 is a graph showing percent inhibition of T cell activation by the synthetic peptide of the present invention. Fig.
4 is a graph showing the inhibitory effect of Th17 cell differentiation on the synthetic peptide of the present invention.
FIG. 5 is a schematic diagram schematically showing the preparation process of the collagen-induced arthritis mouse model and the administration time of the peptide according to the present invention.
6 is a graph showing the effect of the Pep1 peptide of the present invention on improving arthritis.
FIG. 7 is a graph showing the arthritis improving effect of the Pep2 peptide of the present invention. FIG.
FIG. 8 is a graph showing the arthritis improving effect of the Pep4 peptide of the present invention. FIG.
9 is a graph showing the arthritis improving effect of the Pep6 peptide of the present invention.
이하, 본 발명의 용어는 하기와 같이 정의한다.Hereinafter, terms of the present invention are defined as follows.
본 발명에서, 천연적으로 존재하는 아미노산에 대한 통상의 1문자 및 3문자 코드가 사용될 뿐만 아니라, Aib(α-아미노이소부티르산), Sar(N-methylglycine) 등과 같은 다른 아미노산에 대해 일반적으로 허용되는 3문자 코드가 사용된다. 또한 본 명세서에서 약어로 언급된 아미노산은 IUPAC-IUB 명명법에 따라 기재되었다.In the present invention, the usual 1-letter and 3-letter codes for naturally occurring amino acids are used, as well as those generally accepted for other amino acids such as Aib (alpha -aminoisobutyric acid), Sar (N-methylglycine) Three character codes are used. Also, the amino acids referred to herein by abbreviations have been described in accordance with the IUPAC-IUB nomenclature.
본 발명의 “펩타이드(peptide)”는 아마이드 결합(또는 펩타이드 결합)으로 연결된 2개 이상의 아미노산으로 이루어진 폴리머를 의미하며, 본 발명의 목적상, 골질환 치료 효과를 가지는 펩타이드를 의미한다.The term " peptide " of the present invention means a polymer composed of two or more amino acids linked by an amide bond (or a peptide bond), and for the purpose of the present invention means a peptide having a bone disease therapeutic effect.
본 발명의, "안정성"은 생체 내 단백질 절단효소의 공격으로부터 본 발명의 펩타이드를 보호하는 인 비보 안정성뿐만 아니라, 저장 안정성(예컨대, 상온 저장 안정성)도 의미한다."Stability" of the present invention also means storage stability (e.g., room temperature storage stability) as well as in vivo stability that protects the peptide of the present invention from attack by a protein cleaving enzyme in vivo.
본 발명의, "예방"은 본 발명에 따른 약학적 조성물의 투여에 의해 질환을 억제시키거나 발병을 지연시키는 모든 행위를 의미한다.By "prophylactic" of the present invention is meant any action which inhibits the disease or delays its development by administration of the pharmaceutical composition according to the invention.
본 발명의, "치료"는 본 발명에 따른 약학적 조성물의 투여에 의해 질환에 대한 증세가 호전되거나 이롭게 변경되는 모든 행위를 의미한다.The term "treatment" of the present invention means any action that improves or alters the symptoms of the disease by administration of the pharmaceutical composition according to the present invention.
본 발명의, "개체"는 질환의 치료를 필요로 하는 대상을 의미하며, 보다 구체적으로 인간 또는 비-인간인 영장류, 생쥐(mouse), 개, 고양이, 말 및 소 등의 포유류를 의미한다.The term "individual" of the present invention means a subject in need of treatment of a disease, and more specifically refers to mammals such as primates, mice, dogs, cats, horses and cattle, which are human or non-human.
본 발명의 "개선"이란 치료되는 상태와 관련된 파라미터, 예를 들면, 증상의 정도를 적어도 감소시키는 모든 행위를 의미한다.&Quot; Improvement "of the present invention means all actions that at least reduce the degree of symptom associated with the condition being treated, for example.
이하, 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 The present invention
하기 서열번호 1로 기재되는 일반식 1의 아미노산 서열로 구성된 펩타이드, 및 상기 펩타이드를 유효성분으로 함유하는 골질환 예방 및 치료용 약학적 조성물을 제공한다:There is provided a peptide comprising the amino acid sequence of the
[일반식 1][Formula 1]
(X1-X2-X3)n (X 1 -X 2 -X 3 ) n
상기 식에서, X1 내지 X3은 각각 프롤린(Proline; P), 세린(Serine; S), 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이고, n은 1 내지 10의 정수이며, 단 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP이면서, 동시에 n=1 내지 3 경우는 제외함.Wherein X 1 to X 3 are each independently selected from the group consisting of proline P, serine S, threonine T, glutamine Q, asparagine N, and cysteine C And n is an integer of 1 to 10, provided that the amino acid sequence of the general formula (1) is the PSP represented by SEQ ID NO: 2 and n = 1 to 3 at the same time.
상기 펩타이드는 상기 일반식 1을 이용하여 다양한 펩타이드를 제조할 수 있으며, 이는 모두 본 발명에 포함된다. 또한, 상기 X1 내지 X3은 각각 프롤린(Proline; P), 세린(Serine; S) 및 트레오닌(Threonine; T)으로 이루어진 군으로부터 선택되는 어느 하나인 것이 바람직하고, 프롤린(Proline; P) 또는 세린(Serine; S)인 것이 보다 바람직하나 이에 한정되지 않는다.The above peptides can be used to produce various peptides using the above
또한, 상기 일반식에서 n은 1 내지 6의 정수인 것이 바람직하고, 1 내지 3인 것이 보다 바람직하다. In the above general formula, n is preferably an integer of 1 to 6, more preferably 1 to 3.
상기 본 발명의 펩타이드는 당해 분야에서 널리 공지된 다양한 방법으로 획득할 수 있다. 일례로서, 폴리뉴클레오타이드 재조합과 단백질 발현 시스템을 이용하여 제조하거나 펩타이드 합성과 같은 화학적 합성을 통하여 시험관 내에서 합성하는 방법, 및 무세포 단백질 합성법 등으로 제조될 수 있다.The peptides of the present invention can be obtained by a variety of methods well known in the art. As an example, it can be produced by polynucleotide recombination and protein expression system, by synthesis in vitro through chemical synthesis such as peptide synthesis, and by cell-free protein synthesis.
또한, 보다 나은 화학적 안정성, 강화된 약리 특성(반감기, 흡수성, 역가, 효능 등), 변경된 특이성(예를 들어, 광범위한 생물학적 활성 스펙트럼), 감소된 항원성을 획득하기 위하여, 펩타이드의 N- 또는 C-말단에 보호기가 결합되어 있을 수 있다. 바람직하게, 상기 보호기는 아세틸기, 플루오레닐 메톡시 카르보닐기, 포르밀기, 팔미토일기, 미리스틸기, 스테아릴기 또는 폴리에틸렌 글리콜(PEG)일 수 있으나, 펩타이드의 개질, 특히 펩타이드의 안정성 증진시킬 수 있는 성분이라면, 제한없이 포함할 수 있다.In addition, to obtain better chemical stability, enhanced pharmacological properties (half-life, absorbency, potency, efficacy, etc.), altered specificity (e.g., broad biological activity spectrum), reduced antigenicity, - A protecting group may be attached at the terminal. Preferably, the protecting group may be an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group or a polyethylene glycol (PEG), but it is preferable to modify the peptide, The ingredients may be included without limitation.
상기 골질환은 관절염, 골다공증, 뼈전이암(bone metastatic cancer), 고형암 뼈전이, 고형암 뼈전이에 의한 근골격 합병증, 악성 종양으로 인한 과칼슘혈증, 다발성 골수종, 원발성(primary) 뼈 종양, 치주질환, 염증성 치조골 흡수질환, 염증성 뼈흡수 질환 및 파게트병(Paget's disease)으로 이루어진 군으로부터 선택되는 어느 하나 이상인 것이 바람직하나 이에 한정되지 않는다.The above bone diseases include osteoarthritis, osteoporosis, bone metastatic cancer, solid tumor bone metastasis, musculoskeletal complications due to solid tumor metastasis, hypercalcemia due to malignant tumors, multiple myeloma, primary bone tumor, periodontal disease, Inflammatory alveolar bone disorder, inflammatory alveolar bone disorder, inflammatory bone resorption disease, Paget's disease, and the like, but is not limited thereto.
또한, 본 발명의 펩타이드를 코딩하는 폴리뉴클레오타이드를 사용해도 동일한 치료 효과를 나타낼 수 있으므로, 본 발명의 펩타이드를 코딩하는 폴리뉴클레오타이드도 본 발명에 포함되는 것이 자명한 사항이다. In addition, polynucleotides encoding the peptides of the present invention are also included in the present invention, since the same therapeutic effects can be obtained by using the polynucleotides encoding the peptides of the present invention.
본 발명의 구체적인 실시예에서, 본 발명자들은 상기 일반식 1[(X1-X2-X3)n]을 이용하여 다양한 펩타이드를 제작하였다(표 1 참고).In a specific embodiment of the present invention, the present inventors prepared various peptides using the above general formula 1 [(X 1 -X 2 -X 3 ) n ] (see Table 1).
또한, 본 발명자들은 상기 펩타이드들의 T 세포 활성 억제 효과를 확인한 결과, 표 1의 펩타이드들은 평균 15 내지 25%까지 T 세포 활성을 유의적으로 억제하며, 이 중 임의적으로 선별한 펩타이드들의 T 세포 활성 억제 효과는 도 1 내지 도 3에 나타내었다(도 1 내도 도 3 참조).As a result of confirming the inhibitory effect of the peptides on the T cell activity, the present inventors found that the peptides of Table 1 significantly inhibited T cell activity by an average of 15 to 25%, and inhibited the T cell activity of arbitrarily selected peptides The effect is shown in Figs. 1 to 3 (see Fig. 3 also in Fig. 1).
또한, 본 발명자들은 상기 <실시예 1>에서 제작한 합성 펩타이드가 Th17 세포 분화를 억제시키는 효능을 확인한 결과, 본 발명의 펩타이드들은 Th17 세포 분화를 유의적으로 억제하는 것을 확인하였다(도 4 참조).In addition, the present inventors confirmed that the synthetic peptides prepared in Example 1 were effective in inhibiting Th17 cell differentiation, and as a result, it was confirmed that the peptides of the present invention significantly inhibited Th17 cell differentiation (see FIG. 4) .
아울러, 본 발명자들은 류마티스 관절염 동물모델을 제작한 후(도 5 참조), 본 발명의 펩타이드들의 치료 효과를 확인한 결과, 유의적인 관절염 개선 효과를 나타내고, 특히 양성대조군 MTX 대비 유사한 효능이 나타내는 것을 확인하였다(도 6 내지 도 9 참조). In addition, the present inventors confirmed the therapeutic effects of the peptides of the present invention after producing an animal model of rheumatoid arthritis (see FIG. 5). As a result, they showed significant arthritis-improving effects and particularly similar effects to the positive control MTX (See Figs. 6 to 9).
따라서, 본 발명의 펩타이드들은 자가면역질환에 관련된 T 세포(T cell)의 활성 및 Th17 세포(T helper 17 cell) 분화를 유의적으로 억제시키며, 관절염 동물모델에서 현저한 관절염 치료 및 개선 효과를 갖는 것을 확인하였으므로, 상기 펩타이드들은 골질환 치료제에 유효성분으로 유용하게 사용될 수 있다.Therefore, the peptides of the present invention significantly inhibit T cell (T cell) activity and Th17 cell (
한편, 본 발명의 펩타이드 또는 이를 코딩하는 폴리뉴클레오타이드는 콜로이드 현탁액, 분말, 식염수, 지질, 리포좀, 미소구체(microspheres), 또는 나노 구형입자와 같은 약학적으로 허용될 수 있는 담체에 운반될 수 있다. 이들은 운반 수단과 복합체를 형성하거나 관련될 수 있고, 지질, 리포좀, 미세입자, 금, 나노입자, 폴리머, 축합 반응제, 다당류, 폴리아미노산, 덴드리머, 사포닌, 흡착 증진 물질 또는 지방산과 같은 당업계에 공지된 운반 시스템을 사용하여 생체 내 운반될 수 있다.Alternatively, the peptides of the invention or polynucleotides encoding them can be delivered to a pharmaceutically acceptable carrier such as a colloidal suspension, powder, saline, lipid, liposome, microspheres, or nanospheric particles. They may be associated with or associated with carriers and may be in the form of lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation reagents, polysaccharides, polyamino acids, dendrimers, saponins, And can be delivered in vivo using known delivery systems.
이 외에도, 약학적으로 허용되는 담체는 제제시 통상적으로 이용되는 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아, 고무, 인산칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세 결정성 셀룰로스, 폴리비닐 피로리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필 히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함할 수 있으나, 이에 한정되는 것은 아니다. 또한, 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.In addition, pharmaceutically acceptable carriers may be formulated with pharmaceutically acceptable carriers such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, But are not limited to, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. Further, in addition to the above components, a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like may be further included.
본 발명의 약학적 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구투여(예를 들어, 근육 내, 정맥 내, 복강 내, 피하, 피내, 또는 국소에 적용)할 수 있으며, 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 시간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.The pharmaceutical composition of the present invention may be administered orally or parenterally (for example, intramuscularly, intravenously, intraperitoneally, subcutaneously, intradermally, or topically) depending on the intended method, The severity and severity of the disease, the form of the drug, the route of administration and the time of administration, may be appropriately selected by those skilled in the art.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에 있어서 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명에 다른 약학적 조성물은 개별 치료제로 투여하거나 다른 골질환 치료제와 병용하여 투여될 수 있고 종래의 골질환 치료제와는 동시에, 별도로, 또는 순차적으로 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, The sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other bone disease therapeutic agents and may be administered simultaneously with the conventional bone disease therapeutic agents separately or sequentially and may be administered singly or multiply . It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
구체적으로 본 발명의 약학적 조성물의 유효량은 환자의 연령, 성별, 상태, 체중, 체내에 활성 성분의 흡수도, 불활성율, 배설 속도, 질병 종류, 병용되는 약물에 따라 달라질 수 있으며, 투여 경로, 비만의 중증도, 성별, 체중, 연령 등에 따라 증감될 수 있다.Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, condition, body weight, absorbency of the active ingredient, inactivity, excretion rate, disease type, The severity of obesity, sex, weight, age, and the like.
아울러, 본 발명은 본 발명의 펩타이드 또는 이를 코딩하는 폴리뉴클레오타이드를 유효성분으로 함유하는 골질환 예방 및 개선용 건강식품을 제공한다.In addition, the present invention provides a health food for prevention and improvement of bone diseases containing the peptide of the present invention or a polynucleotide encoding the same as an active ingredient.
상기 건강식품은 질환의 예방 또는 개선을 위하여 해당 질환의 발병 단계 이전 또는 발병 후, 치료를 위한 약제와 동시에 또는 별개로서 사용될 수 있다.The health food may be used either simultaneously with or separately from the medicament for treatment before or after the onset of the disease for the prevention or improvement of the disease.
본 발명의 건강식품에서, 유효성분을 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합량은 그의 사용 목적(예방 또는 개선용)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 조성물은 원료에 대하여 바람직하게 15 중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가될 수 있다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있다.In the health food of the present invention, the active ingredient may be directly added to the food or may be used together with other food or food ingredients, and suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (for prevention or improvement). In general, the composition of the present invention may be added in an amount of preferably not more than 15% by weight, preferably not more than 10% by weight, based on the raw material. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range.
본 발명의 건강식품은 상기 유효성분을 함유하는 것 외에 특별한 제한없이 다른 성분들을 필수 성분으로서 함유할 수 있다. 예를 들면, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당 알코올일 수 있다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어, 레바우디오시드 A, 글리시르히진 등)) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 당업자의 선택에 의해 적절하게 결정될 수 있다.The health food of the present invention may contain other ingredients as an essential ingredient without any particular limitations other than those containing the active ingredient. For example, various flavoring agents or natural carbohydrates may be added as an additional ingredient, such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. (Such as taurine, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (such as saccharin and aspartame) are advantageously used as flavorings other than those described above . The ratio of the natural carbohydrate can be appropriately determined by a person skilled in the art.
상기 외에 본 발명의 건강식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있으며, 이러한 첨가제의 비율 또한 당업자에 의해 적절히 선택될 수 있다.In addition to the above, the health food of the present invention may further contain various additives such as various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, Salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. These components can be used independently or in combination, and the proportion of such additives can also be appropriately selected by those skilled in the art.
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the present invention is not limited to the following Examples and Experimental Examples.
<실시예 1> 펩타이드의 제작Example 1 Production of Peptide
하기 [일반식 1]을 기초로 다양한 펩타이드를 제작하였다. 이후, 고성능 액체크로마토그래피(SHIMADZU Prominence HPLC)를 이용하여 합성된 펩타이드 각각을 순수 분리하였으며, 컬럼은 Shiseido capcell pak C18 Column(4.6 × 50 mm)을 이용하였다. 또한, 질량분석기(HP 1100 series LC/MSD)를 이용하여, 합성된 펩타이드 각각의 질량을 확인하였다.Various peptides were prepared based on the following [Formula 1]. Then, each peptide synthesized by high performance liquid chromatography (SHIMADZU Prominence HPLC) was purified and the column was used Shiseido capcell pak C18 column (4.6 × 50 mm). The mass of each of the synthesized peptides was confirmed using a mass spectrometer (HP 1100 series LC / MSD).
[일반식 1][Formula 1]
(X1-X2-X3)n (X 1 -X 2 -X 3 ) n
상기 식에서, X1 내지 X3은 각각 프롤린(Proline; P), 세린(Serine; S), 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이고, Wherein X 1 to X 3 are each independently selected from the group consisting of proline P, serine S, threonine T, glutamine Q, asparagine N, and cysteine C ), ≪ / RTI >
n은 1 내지 10의 정수이며, 단 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP이고, 동시에 n=1 내지 3 경우는 제외함. n is an integer of 1 to 10, provided that the amino acid sequence of the
아울러, 상기 방법으로 합성된 펩타이드를 하기 표 1에 일부 나열하였다.In addition, the peptides synthesized by the above method are listed in Table 1 below.
<실험예 1> T 세포 활성 억제 효과 확인<Experimental Example 1> Confirmation of T cell activity inhibitory effect
상기 <실시예 1>에서 제작한 합성 펩타이드의 T 세포 활성 억제 효능을 확인하기 위하여, 마우스의 림프절에서 추출한 T 세포를 사용하여 ex vivo 활성 억제 실험을 수행하였다.In order to confirm the T cell activity inhibitory effect of the synthetic peptide prepared in Example 1 above, ex vivo activity inhibition experiments were carried out using T lymphocytes extracted from mouse lymph nodes.
구체적으로, 먼저, T 세포의 활성화를 유도하기 위하여 96 well plate에 CD3 항체를 coating하여 4℃에서 overnight 동안 incubation 하여 CD3항체가 붙어있는 96 well을 제작하였다. 그 후, 마우스에서 추출한 naive T 세포를 96 well plate에 1×105/well 씩 seeding 하고 상기 <실시예 1>에서 제작한 각 합성 펩타이드를 처리하여 18시간 동안 배양한 후 flow cytometry 방법으로 활성 T 세포의 population을 확인하였다. 이를 위해, 배양한 각각의 그룹에서 동일한 숫자의 세포를 collection 하고 PBS로 wash 과정을 거친 뒤, helper T 세포 마커인 rabbit anti-mouse CD4와 T 세포의 활성화 마커인 rabbit anti-mouse CD69 항체를 사용하여 staining 과정을 수행하였다. PBS로 washing한 뒤, CD4+CD69+ T 세포 population 을 분석하였다. Specifically, to induce T cell activation, CD3 antibody was coated on a 96-well plate and incubated overnight at 4 ° C to prepare 96 wells with CD3 antibody. Then, the naive T cells extracted from the mouse were seeded at a density of 1 × 10 5 / well on a 96-well plate, treated with each of the synthetic peptides prepared in Example 1 for 18 hours, and then subjected to flow cytometry to obtain active T The population of cells was confirmed. For this purpose, the same number of cells were collected from each cultured group, washed with PBS, and then rabbit anti-mouse CD4, a helper T cell marker, and rabbit anti-mouse CD69 antibody, staining procedure. After washing with PBS, CD4 + CD69 + T cell population was analyzed.
그 결과, 상기 <실시예 1>에서 합성한 펩타이드는 평균 15 내지 25%까지 T 세포 활성을 유의적으로 억제하는 것을 확인하였다.As a result, it was confirmed that the peptides synthesized in Example 1 significantly inhibited T cell activity by an average of 15 to 25%.
또한, 상기 <실시예 1>에서 합성한 펩타이드 중, 표 2에 나타낸 펩타이드의 T 세포 활성 억제효과에 대해서는 도 1 내지 도 3에 나타내었다.Among the peptides synthesized in Example 1, the inhibitory effects of the peptides shown in Table 2 on T cell activity are shown in FIGS. 1 to 3.
구체적으로, 활성화를 유도하지 않은 그룹 (0.98%)에 비해 CD3 항체로 활성화 시킨 그룹에서 활성 T 세포가 74.8%로 증가하였고, 각 합성 펩타이드를 처리한 그룹에서는 55 ~ 62 % 까지 감소하는 것을 확인하였다. 또한, 각각의 합성 펩타이드의 활성 T 세포 억제율은 <실시예 1>에서 합성한 펩타이드와 동일하게 약 15% 에서 최대 25%임을 확인하였다.Specifically, it was confirmed that the activation T cells were increased to 74.8% in the CD3 antibody-activated group and decreased to 55 to 62% in the group treated with each synthetic peptide compared with the group without activation (0.98%) . In addition, it was confirmed that the inhibitory rate of active T cells of each synthetic peptide was about 15% to 25% as in the case of the peptide synthesized in Example 1.
따라서, 본원발명의 합성 펩타이드는 T 세포 활성을 유의적으로 억제하여 골질환 치료에 사용될 수 있음을 확인하였다(도 1 내지 도 3).Thus, it was confirmed that the synthetic peptide of the present invention can be used for the treatment of bone diseases by significantly inhibiting T cell activity (FIGS. 1 to 3).
<실험예 2> Th 17 세포 분화 억제 효과 확인<Experimental Example 2> Confirmation of inhibitory effect of
상기 <실시예 1>에서 제작한 합성 펩타이드가 Th17 세포 분화를 억제시키는 효능을 확인하기 위하여, 마우스의 림프절에서 추출한 naive CD4+ T 세포에 TCR activation과 함께 IL-6 20 ng/ml과 TGF-beta 5 ng/ml을 처리하여 Th17 세포로 분화를 유도하였다. In order to confirm the efficacy of the synthetic peptides prepared in Example 1 to inhibit Th17 cell differentiation, naive CD4 + T cells extracted from mouse lymph nodes were incubated with 20 ng / ml of IL-6 and TGF-
동시에 상기 <실험예 1>의 표 2에 개시된 펩타이드 3종 (Pep2, Pep3, Pep4) 을 10 ~ 1000 ng/ml의 농도로 각각 처리하였다. 그런 다음, 3일동안 incubation 한 뒤, CD4+IL-17+ T 세포 population 을 분석하였다. At the same time, the three peptides (Pep2, Pep3, Pep4) shown in Table 2 of <Experimental Example 1> were treated at a concentration of 10 to 1000 ng / ml. After incubation for 3 days, CD4 + IL-17 + T cell populations were analyzed.
그 결과, 도 4에 나타낸 바와 같이, Th17 세포로 분화를 유도하지 않은 그룹 (1.2%)에 비해 Th17 분화를 유도한 그룹에서 약 2.5배 증가하는 경향이 보였으며 (3.14%), Pep2, Pep3, Pep4 펩타이드를 각각 처리한 그룹에서는 분화를 유도하지 않은 그룹과 유사하게 Th17 세포의 비율이 감소하는 것을 확인하였다(도 4).As a result, as shown in FIG. 4, the group which induced Th17 differentiation showed a tendency to increase about 2.5 times (3.14%) in the group inducing Th17 differentiation compared to the group that did not induce differentiation into Th17 cells (1.2% In the groups treated with Pep4 peptides, it was confirmed that the proportion of Th17 cells was decreased similarly to the group not inducing differentiation (Fig. 4).
<실험예 3> Collagen-induced arthritis (CIA) mouse model을 이용한 류마티스 관절염 치료 효과 확인<Experimental Example 3> Effect of a collagen-induced arthritis (CIA) mouse model on the treatment effect of rheumatoid arthritis
<3-1> 류마티스 관절염 마우스 모델의 제작<3-1> Production of mouse model of rheumatoid arthritis
상기 <실시예 1>에서 제작한 펩타이드의 류마티스 관절염 개선 효과를 확인하기 위하여, 공지 문헌(Nat Protoc. 2007;2(5):1269-75.)을 참고하여 류마티스 관절염 마우스 모델을 제작하였다.A rheumatoid arthritis mouse model was prepared by referring to the known literature (Nat Protoc. 2007; 2 (5): 1269-75) in order to confirm the effect of the peptide prepared in Example 1 for improving rheumatoid arthritis.
구체적으로, CIA mouse model은 인간의 류마티스 관절염과 유사한 특징을 보이는 자가면역질환 관절염 모델로 류마티스 관절염 동물실험에서 가장 흔히 쓰이는 마우스 모델이다. CIA 마우스 모델은 먼저, 소의 제 2형 콜라겐(Bovine type II collagen, Chondrex, USA)과 프로인트 완전 보조제(Freund’s complete adjuvant, Chondrex, USA)를 1:1로 혼합하여 에멀젼화한 후, 에멀젼화된 콜라겐 용액 50 ul를 6주령의 DBA/1J 마우스 꼬리에 피내 주사하여 1차 면역(immunization) 시켰다. 1차 면역 후, 2주 째에 소의 제 2형 콜라겐과 프로인트 불완전 보조제(Freund’s incomplete adjuvant, Chondrex, USA)를 1:1로 혼합하여 에멀젼화한 후, 에멀젼화된 콜라겐 용액 50 ul를 마우스 꼬리에 피내 주사하여 2차 면역(boosting)을 유도하였다. 2차 면역 후, 다음날부터 1주일에 3회씩 각 펩타이드를 복강 투여하여 펩타이드의 류마티스 관절염 치료효과를 관찰하였다. 투여 펩타이드는 표 2에 개시된 펩타이드 4종(Pep1, Pep2, Pep4, Pep6)로 선정하였다(도 5).Specifically, the CIA mouse model is an autoimmune disease arthritis model similar to human rheumatoid arthritis, and is the most commonly used mouse model in rheumatoid arthritis animal experiments. CIA mice were first emulsified by mixing 1: 1 of bovine type II collagen (Bovine type II collagen, Chondrex, USA) and Freund's complete adjuvant (Chondrex, USA) 50 μl of collagen solution was injected intradermally into the tail of DBA / 1J mouse at 6 weeks of age to perform primary immunization. After the first immunization,
<3-2> 류마티스 관절염 마우스 모델을 이용한 치료 효과 확인<3-2> Confirmation of therapeutic effect using rheumatoid arthritis mouse model
본 발명의 펩타이드 처리에 따른 류마티스 관절염 진행 추이를 살피고자, 시간의 경과에 따른 류마티스 관절염의 심화 정도를 류마티스 관절염 진행 지수로 평가하여 측정하였다.In order to examine the progress of rheumatoid arthritis progression according to the peptide treatment of the present invention, the degree of progression of rheumatoid arthritis with time was evaluated by evaluating the rheumatoid arthritis progression index.
구체적인 실험 조건에 대해서 알지 못하는 관찰자 두 명이 일주일에 세 번씩, 관절염 진행 정도를 평가하였다. 이때, 관절염 진행 지수는, 하기 표 2의 Rossoliniec 등에 의한 관절염 진행 평가 기준에 따라 각 다리당 0점 내지 4점으로 평가하여 총 0점 내지 16점(네 다리 합산)으로 나타내었으며, 이후, 두 명의 관찰자가 평가한 결과의 평균 값을 산출하여 관절염의 중증도를 수치화하였다. Two observers who were unaware of the specific experimental conditions assessed the progression of arthritis three times a week. At this time, the arthritic progression index was expressed as 0 to 16 points (total of four legs) in total by evaluating the arthritic progression index from 0 to 4 points for each leg according to Rossoliniec et al. The severity of arthritis was quantified by calculating the average value of the results evaluated by the observer.
그 결과, 도 6 내지 도 9에 나타낸 바와 같이 정상 마우스(normal) 그룹과 비교하여, CIA를 유발한 마우스(Vehicle control; PBS)에서 관절염 스코어가 현저하게 증가하는 것을 알 수 있으며, 펩타이드 4종(Pep1, Pep2, Pep4, Pep6)을 각각 복강투여한 그룹에서 관절염 개선 효능이 나타나는 것을 확인하였다. 또한, 양성대조군 MTX 대비 유사한 효능이 나타내는 것을 확인하였다(도 6 내지 도 9). As a result, as shown in FIGS. 6 to 9, it can be seen that the arthritic score is significantly increased in the CIA-induced mouse (Vehicle control) compared with the normal mouse group, Pep1, Pep2, Pep4, and Pep6) were intraperitoneally administered, respectively. In addition, it was confirmed that similar efficacy was shown to the positive control MTX (Figs. 6 to 9).
따라서, 본 발명의 펩타이드가 관절염을 포함하는 다양한 골질환 치료제로 사용할 수 있음을 확인하였다.Therefore, it was confirmed that the peptide of the present invention can be used as a therapeutic agent for various bone diseases including arthritis.
<110> SOOKMYUNG WOMEN UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION <120> Use of a peptide as a therapeutic agent for bone disease <130> PB2017-114 <160> 2 <170> KoPatentIn 3.0 <210> 1 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> PEPTIDE <220> <221> MISC_FEATURE <222> (1)..(3) <223> Xaa is Proline, Serine, Threonine, Glutamine OR Asparagine <400> 1 Xaa Xaa Xaa 1 <210> 2 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> PEPTIDE <400> 2 Pro Ser Pro 1 <110> SOOKMYUNG WOMEN UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION <120> Use of a peptide as a therapeutic agent for bone disease <130> PB2017-114 <160> 2 <170> KoPatentin 3.0 <210> 1 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> PEPTIDE <220> <221> MISC_FEATURE <222> (1) (3) <223> Xaa is Proline, Serine, Threonine, Glutamine OR Asparagine <400> 1 Xaa Xaa Xaa One <210> 2 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> PEPTIDE <400> 2 Pro Ser Pro One
Claims (9)
[일반식 1]
(X1-X2-X3)n
상기 식에서, X1 내지 X3은 각각 프롤린(Proline; P), 세린(Serine; S), 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이고,
n은 1 내지 10의 정수이며, 단 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP이고, 동시에 n=1 내지 3 경우는 제외함.
A peptide consisting of the amino acid sequence of the general formula 1 described in SEQ ID NO: 1 below:
[Formula 1]
(X 1 -X 2 -X 3 ) n
Wherein X 1 to X 3 are each independently selected from the group consisting of proline P, serine S, threonine T, glutamine Q, asparagine N, and cysteine C ), ≪ / RTI >
n is an integer of 1 to 10, provided that the amino acid sequence of the general formula 1 is the PSP represented by SEQ ID NO: 2, and n = 1 to 3 are excluded.
The peptide according to claim 1, wherein X 1 to X 3 are each selected from the group consisting of proline (P), serine (S) and threonine (T).
The peptide according to claim 1, wherein X 1 to X 3 are each proline (P) or serine (S).
The peptide according to claim 1, wherein n is an integer of 1 to 6.
The peptide according to claim 1, wherein n is an integer of 1 to 3.
The peptide according to claim 1, wherein the N- or C-terminal of the peptide is selected from the group consisting of an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group and a polyethylene glycol (PEG) Wherein said peptide is coupled to a selected protecting group.
[일반식 1]
(X1-X2-X3)n
상기 식에서, X1 내지 X3은 각각 프롤린(Proline; P), 세린(Serine; S), 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이고,
n은 1 내지 10의 정수이며, 단 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP이고, 동시에 n=1 내지 3 경우는 제외함.
1. A pharmaceutical composition for the prevention and treatment of bone disease comprising, as an active ingredient, a peptide consisting of the amino acid sequence of the general formula 1 described in SEQ ID NO: 1 below:
[Formula 1]
(X 1 -X 2 -X 3 ) n
Wherein X 1 to X 3 are each independently selected from the group consisting of proline P, serine S, threonine T, glutamine Q, asparagine N, and cysteine C ), ≪ / RTI >
n is an integer of 1 to 10, provided that the amino acid sequence of the general formula 1 is the PSP represented by SEQ ID NO: 2, and n = 1 to 3 are excluded.
8. The method of claim 7, wherein the bone disease is selected from the group consisting of arthritis, osteoporosis, bone metastatic cancer, solid tumor bone metastasis, musculoskeletal complications due to solid tumor metastasis, hypercalcemia due to malignancy, multiple myeloma, A bone tumor, periodontal disease, inflammatory alveolar bone disorder, inflammatory bone resorption disease, Paget's disease, and the like.
[일반식 1]
(X1-X2-X3)n
상기 식에서, X1 내지 X3은 각각 프롤린, 세린, 트레오닌, 글루타민, 아스파라긴 및 시스테인으로 이루어진 군으로부터 선택되는 어느 하나이고,
n은 1 내지 10의 정수이며, 단 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP이고, 동시에 n=1 내지 3 경우는 제외함.
1. A health food for preventing and improving bone diseases comprising as an active ingredient a peptide consisting of the amino acid sequence of the general formula 1 described in SEQ ID NO: 1 below,
[Formula 1]
(X 1 -X 2 -X 3 ) n
Wherein X 1 to X 3 are each selected from the group consisting of proline, serine, threonine, glutamine, asparagine and cysteine,
n is an integer of 1 to 10, provided that the amino acid sequence of the general formula 1 is the PSP represented by SEQ ID NO: 2, and n = 1 to 3 are excluded.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020515231A JP7122018B2 (en) | 2017-09-15 | 2018-09-14 | Use of Peptides as Therapeutic Agents for Autoimmune and Bone Diseases |
| US16/646,069 US11629169B2 (en) | 2017-09-15 | 2018-09-14 | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
| CA3075607A CA3075607A1 (en) | 2017-09-15 | 2018-09-14 | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
| AU2018332486A AU2018332486B2 (en) | 2017-09-15 | 2018-09-14 | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
| PCT/KR2018/010873 WO2019054808A2 (en) | 2017-09-15 | 2018-09-14 | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
| US18/174,730 US20230234985A1 (en) | 2017-09-15 | 2023-02-27 | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170118947 | 2017-09-15 | ||
| KR20170118947 | 2017-09-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190031182A true KR20190031182A (en) | 2019-03-25 |
| KR102166930B1 KR102166930B1 (en) | 2020-10-19 |
Family
ID=65907963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180110473A KR102166930B1 (en) | 2017-09-15 | 2018-09-14 | Use of a peptide as a therapeutic agent for autoimmune disease or bone disease |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102166930B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140087997A1 (en) * | 2011-05-11 | 2014-03-27 | Technion Research & Development Foundtion Limited | Anti-microbial peptides and uses of same |
| WO2016204841A1 (en) * | 2015-06-17 | 2016-12-22 | Avon Products, Inc. | Peptides and their use in the treatment of skin |
-
2018
- 2018-09-14 KR KR1020180110473A patent/KR102166930B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140087997A1 (en) * | 2011-05-11 | 2014-03-27 | Technion Research & Development Foundtion Limited | Anti-microbial peptides and uses of same |
| WO2016204841A1 (en) * | 2015-06-17 | 2016-12-22 | Avon Products, Inc. | Peptides and their use in the treatment of skin |
Non-Patent Citations (6)
| Title |
|---|
| Anishetty 등, BMC Structural Biology 2002, 2, available from: http://www.biomedcentral.com/1472-6807/2/9* * |
| Banerji 등, J. Phys. Chem. B 2017, 121, 6367-6379* * |
| Bauer 등, Biochemical and Biophysical Research Communications 406 (2011) 348-352* * |
| Grewal 등, J. Phys. Chem. B 2004, 108, 4899-4908* * |
| Hunt & Dayhoff, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS Vol. 39, No. 4, 1970, 757-765* * |
| Krause 등, Inorg. Chem. 2010, 49, 362-364* * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102166930B1 (en) | 2020-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6573293B2 (en) | Peptide for preventing or treating inflammatory diseases and use thereof | |
| KR102166930B1 (en) | Use of a peptide as a therapeutic agent for autoimmune disease or bone disease | |
| KR102166928B1 (en) | Use of a peptide as a therapeutic agent for autoimmune disease or bone disease | |
| US20230234985A1 (en) | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases | |
| US20240009264A1 (en) | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases | |
| KR102166927B1 (en) | Use of a peptide as a therapeutic agent for autoimmune disease | |
| KR102166929B1 (en) | Use of a peptide as a therapeutic agent for autoimmune disease | |
| CN111148525B (en) | Use of peptides as therapeutic agents for autoimmune diseases and bone diseases | |
| CN111093687B (en) | Use of peptides as therapeutic agents for autoimmune diseases and bone diseases | |
| KR102219928B1 (en) | Use of a peptide as a therapeutic agent | |
| KR102164417B1 (en) | Use of a peptide as a therapeutic agent | |
| WO2019054808A2 (en) | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases | |
| KR102219927B1 (en) | Use of a peptide as a therapeutic agent | |
| KR102219926B1 (en) | Use of a peptide as a therapeutic agent | |
| WO2019054809A2 (en) | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases | |
| KR20240086945A (en) | Peptide for cartilage regeneration and uses thereof | |
| KR20240094145A (en) | Peptide for cartilage regeneration and uses thereof | |
| KR20240086940A (en) | Peptide for cartilage regeneration and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| N231 | Notification of change of applicant | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |